Please refer to our letter dated August 10, 2020 wherein we have intimated the schedule of Investors/ Analysts call on August 13, 2020. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first Quarter ended June 30, 2020. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/

Please refer to our letter dated August 3, 2020 wherein we have informed that the Register of Members and Share Transfer Books of the Company are being closed from August 25, 2020 to August 27, 2020 (both days inclusive) for the purpose of 33rd Annual General Meeting of the Company. We hereby further inform that the aforesaid book closure dates will also be considered to determine the entitlement of the shareholders to the aforesaid interim dividend of 125% i.e Rs.1.25 (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the year 2020-21 as approved by the Board on August 12, 2020 and the same will be paid on or before September 4, 2020.

Aurobindo Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 12, 2020, inter alia, has approved an Interim Dividend @ 125% i.e. Rs. 1.25 (Rupee one and paise twenty five) per equity share of Re. 1/- each on the equity share capital of the Company for the Financial Year 2020-21.

The Board of Directors of the Company at its meeting held today, August 12, 2020, has, inter alia, transacted the following business: Approved an Interim Dividend @ 125% i.e Rs.1.25 (Rupee one and paise twenty five) per equity share of Re.1 each on the equity share capital of the Company for the Financial Year 2020-21.

The Board of Directors of the Company at its meeting held today, August 12, 2020, has, inter alia, transacted the following businesses: 1. Approved the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company. 2. Approved an Interim Dividend @ 125% i.e Rs.1.25 (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2020-21. We also enclose a copy of the Press Release on Un-audited Financial Results of the Company for the First Quarter ended June 30, 2020.

The Board of Directors of the Company at its meeting held today, August 12, 2020, has, inter alia, transacted the following businesses: 1. Approved the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company. 2. Approved an Interim Dividend @ 125% i.e Rs.1.25 (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2020-21. The Board meeting commenced at 4.00 p.m. and concluded at 7.00 p.m.